REALM PROJECT
REopening Archives, Libraries, and Museums

Briefing: Vaccines, Variants, and Ventilation

A Briefing on Recent Scientific Literature Focused on SARS-CoV-2 Vaccines and Variants, Plus the Effects of Ventilation on Virus Spread

Dates of Search: 01 January 2021 through 01 November 2021

Published: 18 November 2021

This document synthesizes various studies and data; however, the scientific understanding regarding COVID-19 is continuously evolving. This material is being provided for informational purposes only, and readers are encouraged to review federal, state, tribal, territorial, and local guidance. The authors, sponsors, and researchers are not liable for any damages resulting from use, misuse, or reliance upon this information, or any errors or omissions herein.

OCLC

INSTITUTE of Museum and Library SERVICES

BATTELLE

INTRODUCTION

Purpose of This Briefing

- Access to the latest scientific research is critical as libraries, archives, and museums (LAMs) work to sustain modified operations during the continuing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.
- As an emerging event, the SARS-CoV-2 pandemic continually presents new challenges and scientific questions. At present, **SARS-CoV-2 vaccines and variants of concern (VOCs) in the US** are two critical areas of focus. The effects of **ventilation-based interventions on the spread of SARS-CoV-2** are also an interest area for LAMs. This briefing provides key information and results from the latest scientific literature to help inform LAMs making decisions related to these topics.

How to Use This Briefing: This briefing is intended to provide timely information about SARS-CoV-2 vaccines, variants of concern, and ventilation to LAMs and their stakeholders. Due to the evolving nature of scientific research on these topics, the information provided here is not intended to be comprehensive or final. As such, this briefing should be used in conjunction with other timely resources to ensure decision-making reflects the latest scientific understanding. Continual re-evaluation of SARS-CoV-2 policies is highly recommended as new scientific discoveries are published.

About This Briefing

- Battelle conducted a systematic search of scientific literature about SARS-CoV-2 vaccines, variants, and ventilation. This briefing summarizes those findings.
- Research questions:
  1. What implications does SARS-CoV-2 vaccination in the US have for public health interventions and policies, especially related to indoor environments?
  2. How do SARS-CoV-2 variants of concern currently circulating in the US differ from the original strain and other variants in terms of spread, transmissibility, surface attenuation, and effectiveness of public health interventions?
  3. What effects do ventilation and ventilation-based interventions (e.g., heating, ventilation, and air conditioning systems (HVAC)) have on the spread of SARS-CoV-2 in indoor environments?
- Dates of search: 01 January 2021 to 01 November 2021. Newest items labeled "[New]"
- Additional information about the methods used to conduct the literature search and create this briefing is included later in the document.

About REALM

REopening Archives, Libraries, and Museums (REALM) is a research project conducted by OCLC, the Institute of Museum and Library Services (IMLS), and Battelle to produce and distribute science-based COVID-19 information that can aid local decision-making regarding operations of archives, libraries, and museums.

View reports published by REALM.

REALM PROJECT

OCLC

INSTITUTE of Museum and Library SERVICES

BATTELLE

BACKGROUND INFORMATION: VACCINES AND VARIANTS

SARS-CoV-2 Vaccines

- The CDC reports updated vaccination numbers daily on a COVID-19 data tracker.[1]
- Three safe and effective vaccines are being distributed, two under the US FDA Emergency Use Authorization and one with full FDA approval: [2, 3]
  - Pfizer-BioNTech: 2-dose series, 21 days apart
    - Full FDA approval on 23 August 2021 for people ages 16 and older.[3]
  - Moderna: 2-dose series, 28 days apart.[5]
  - Janssen (Johnson & Johnson) (J&J): Single dose.[6]
- CDC recommends individuals get the first vaccine that is available for their age group.[4]
- The US government has made vaccines free, and they are widely available now.[7]

Total Doses Administered Reported to the CDC by State/Territory per 100,000 of the Total Population (as of 16 November 2021)



**Vaccination rates by county are also available

To find local vaccination sites: visit Vaccines.gov, text a zip code to 438829, or call 800-232-0233.

REALM PROJECT

OCLC

INSTITUTE of Museum and Library SERVICES

BATTELLE

SARS-CoV-2 Vaccines

- CDC recommends that everyone age 5 or older receive a COVID-19 vaccine.[7] [New]
  - [New] Some people who got the Pfizer-BioNTech and Moderna vaccines can get a booster at least 6 months after their primary vaccine series, including people who are 65 and older, aged 18+ who live in long-term care settings, aged 18+ with underlying medical conditions, or aged 18+ who live or work in high-risk settings.[8]
  - [New] People 18 years and older who received the Johnson & Johnson (J&J) vaccine **should** receive a booster shot at least 2 months after their primary vaccine dose. [8]
  - CDC recommends an additional dose of mRNA vaccine (e.g., Pfizer or Moderna) at least 28 days after the second dose for people with moderately or severely compromised immune systems.[9]
  - CDC noted increased reports of heart-related inflammation in teens and young adults after COVID-19 vaccination, but COVID-19 vaccination is still recommended for everyone age 12 or older because benefits continue to outweigh risks.[4]
  - On 13 July 2021, FDA reported an observed increased risk of Guillain-Barré Syndrome (GBS) after J&J vaccination. Vaccine fact sheets now note that adverse events suggest increased risk of GBS and J&J vaccine recipients with GBS symptoms should seek medical attention.[10]
- CDC continues to review infection rates across the country and release guidance on precautions that both vaccinated and non-vaccinated people should take to stop the spread of COVID-19.[11]
- Lists of what may and may not be safe to change after full vaccination are on the CDC website.

Variants of SARS-CoV-2

What is a Variant?

- **Viruses inherently replicate, which can result in genetic changes or mutations**. After enough mutations occur, the new version is called a variant. Multiple SARS-CoV-2 variants have been found in the US and abroad.
- Sometimes new variants emerge and disappear, and other times new variants emerge and persist.[12]

Types of Variants[13]

- There are now four categories of variants classified by the US government. The types differ based on the possibility of the variant to affect people negatively, such as increased transmissibility. In order from least to most negative effects:
  - Variants Being Monitored (VBM)
  - Variants of Interest (VOI)
  - Variants of Concern (VOC)
  - Variants of High Consequence (VOHC)
- As of this report, in the US there are 10 VBM, 0 VOI, 1 VOC, and 0 VOHC.[13]

Why is it important to track variants?

Monitoring variants can help find out:

- How the virus changes over time into new variants
- How these changes affect aspects of the virus
- How the changes might impact health.[13]

Variants of SARS-CoV-2

CDC Variants of Concern (VOC)

"A variant for which there is evidence of an increase in transmissibility, more severe disease (e.g., increased hospitalizations or deaths), significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures."[13]

Information about reported cases of variants by region and state is available from the CDC.

Current CDC Variant(s) of Concern in the US (as of 16 November 2021)[12]

Variant	WHO Label	First Detected	Other Names
B.1.617.2	Delta	India	20A/S:478K

Note: CDC recently re-classified 3 VOCs as well as 7 VOIs into a new, lower-risk class called Variants Being Monitored (VBM). VBMs are variants for which data suggest the variants can cause severe disease and increased transmission, but they are no longer common in the US and thus currently pose minimal risk in the US. See the current list of VBMs.[14]

What does neutralization mean?
Neutralization is when antibodies, part of the body's defense, bind to a virus and block infection. Vaccines cause the body to build up the antibodies that inhibit viruses.[15]

SUMMARY OF FINDINGS: SYSTEMATIC SEARCH OF SCIENTIFIC LITERATURE ABOUT SARS-COV-2 VACCINES, VARIANTS OF CONCERN, AND VENTILATION

Studies About SARS-CoV-2 Vaccines

Studies About SARS-CoV-2 Vaccines

The Kaiser Family Foundation COVID-19 Vaccine Monitor is an ongoing research project that utilizes surveys and qualitative data to track the US public's attitudes and experiences with COVID-19 vaccines.[16]



[New] Key Findings from October 2021 Monitor

- Vaccine uptake among adults has slowed.
- Vaccine uptake has slowed among 12-17 year-olds. Half of parents say their teen is vaccinated or will be as soon as possible.
- About 27% of parents of 5- to 11-year-olds plan to get a vaccine for their children as soon as one is authorized, while a third say they will wait to see how the vaccine is working.
- Parents have concerns about long-term COVID-19 vaccine effects, side effects, and children's future fertility.
- There are still large gaps in vaccine uptake by political affiliation, education attainment, age, and rural/urban dwellers.
- 40% of fully vaccinated adults are unsure about whether they are eligible to get a COVID-19 booster shot.
- 25% of workers say their employer has required them to get the COVID-19 vaccine, up 16 percentage points since June.

Studies About SARS-CoV-2 Vaccines

Impact of Vaccines and Safety

- Studies continue to show that COVID-19 vaccines offer protection against the infectiousness, transmissibility, and disease burden of SARS-CoV-2,[17-33, 34][New] including among adolescents.[35][New]
  - The US FDA recently amended the emergency use authorizations (EUAs) for both the Pfizer-BioNTech and Moderna COVID-19 vaccines to allow for a third dose in certain immunocompromised individuals, including transplant patients.[36,37]
  - [New] Some studies have found that vaccines offer waning immunity over time, which has led to increased calls for additional booster doses.[38-40]
  - A study in Health Affairs estimates that vaccinations against COVID-19 may have averted up to 140,000 deaths in the US as of May 2021.[41]
- Vaccine safety is assessed during the development process and is still continuously monitored.[42-50] While states have expanded vaccine eligibility, surveys continue to show “vaccine hesitancy” remains a concern for ensuring equitable vaccination coverage.[51,52]
- Rare serious adverse events have been reported after COVID-19 vaccination, including myocarditis, Guillain-Barré syndrome (GBS), and thrombosis with thrombocytopenia syndrome (TTS).[53]
  - [New] Myocarditis, in particular, has been found to be more prevalent in young men.[54-56]
  - The Advisory Committee on Immunization Practices (ACIP) determined that the benefits of COVID-19 vaccination in preventing COVID-19 morbidity and mortality outweigh the risks for these rare serious adverse events.[53]

Studies About SARS-CoV-2 Vaccines

Vaccine Hesitancy

- Factors potentially related to vaccine hesitancy include concerns over vaccine safety, trust in government recommendations, perceived political interference, education, income, race/ethnicity, perceived threat of COVID-19, and experience with racial discrimination.[57-64]

Vaccine Booster Shots

- Although the two-dose regimen of the Pfizer-BioNTech vaccine remains effective against severe disease and hospitalizations, clinical trial data show that a third booster dose (administered 7 to 9 months after primary two-dose series) could provide prolonged protection.[65] This is particularly important for those at highest risk, including the immunocompromised.[66][New]
- Israeli studies have found that booster shots are effective in both elderly populations and the general population.[67, 68][New]
- Some experts have questioned the need for booster doses for the general population at this time.[69]

Studies About SARS-CoV-2 Vaccines

Breakthrough Infections After Vaccination

- Fully vaccinated individuals needing emergency care due to COVID-19 is a rare occurrence. One article reported that when hospital treatment is required; however, elderly patients with comorbidities are at high risk for serious illness regardless of vaccination status.[70]
- Breakthrough infections tend to have milder symptoms and shorter periods of illness. One study found that among 1,497 fully vaccinated healthcare workers, 39 had documented SARS-CoV-2 infections. Most were mild or asymptomatic, but some did have symptoms persist 6 or more weeks.[71,72]
- An observational study found that a small proportion of individuals (0.5% of people who received one dose, and 0.2% of people who received two doses) still became infected with SARS-CoV-2 after vaccination, with higher risk found for older, frail adults and those living in “high deprivation” (i.e., low socioeconomic status) areas.[73]
- A letter in the *New England Journal of Medicine* attributed the increase in breakthrough infections among California healthcare workers to “both the emergence of the Delta variant and waning immunity over time, compounded by the end of masking requirements in California and the resulting greater risk of exposure” for healthcare workers (p. 2). The authors concluded that these results indicate a need for rapid reinstatement of nonpharmaceutical interventions (e.g., wearing masks indoors) and increased vaccination efforts.[74]

Studies About SARS-CoV-2 Vaccines

Impact of Vaccines: Subpopulations

- **Older Adults:** In the US, vaccines are effective and there has been a decrease in COVID-19 cases, emergency department visits, hospital admissions, and deaths among older adults, which are the age group with the highest vaccination rates. The elderly population needs to be closely monitored after vaccination and may require earlier revaccination and/or increased vaccine dose.[75-77]
- **Pregnant women:** Preliminary findings of vaccine safety (for mRNA vaccines) for pregnant persons did not show any obvious safety signals to pregnancy or neonatal outcomes, but continued monitoring is recommended.[78-81][New]
- **Rural:** Residents of rural communities continue to report lower rates of vaccination compared to urban and suburban areas.[16, 82]
- **Adolescents:** Studies have found that the Pfizer-BioNTech vaccine has a favorable safety profile and is highly effective against COVID-19 in 12- to 15-year-olds. In May 2021, FDA emergency use authorization was expanded to include persons 12 years of age or older based on the data from this study.[83-86] Adolescents reported that they are interested in getting the vaccine but have concerns about possible adverse effects.[87]
- [New] **Immunocompromised:** Immunocompromised persons (including transplant recipients, people living with HIV infection, and advanced chronic liver disease patients) are more vulnerable to infections and are at high risk of mortality if complicated with COVID-19 infections.[66, 88]

Studies About SARS-CoV-2 Vaccines

Health Communication and Misinformation

- Scientists have called for efforts to address miscommunication and misinformation on COVID-19 vaccines and restore trust in health authorities.[89-91] Vaccine acceptance will be impeded by misinformation and poor public health communication strategies.[91-93]
- A rapid expert consultation recommended emphasizing support for vaccines, leveraging endorsements, focusing on hesitant individuals, and engaging communities to increase confidence in vaccines.[94]

Reaching High-risk Populations

- Equitable access to COVID-19 vaccines among racial/ethnic minorities is a key concern,[95][New] as Hispanics and Blacks are less likely to have had at least one vaccine dose compared to Whites and Asians.[96]
- Researchers have identified that COVID-19 continues to disproportionally impact the Black community, further worsening health disparities already present due to racism and its effects on social and economic factors.[52,97-101] Efforts also need to be made to improve access among persons in low socioeconomic (SES) areas and persons with disabilities.[102, 103][New]

What Research is Still Needed About SARS-CoV-2 Vaccines? [2,11,104]

- How long immunity lasts for different vaccines
- How well the vaccines keep people from spreading SARS-CoV-2 to others, even without symptoms
- How well different vaccines will protect against future SARS-CoV-2 variants
- How well vaccines protect people with weakened immune systems and other sub-populations (elderly, pregnant women, children/adolescents)

Key CDC Resources About SARS-CoV-2 Vaccines

- CDC website - Vaccines for COVID-19
- COVID-19 Community, Work, & School Toolkit
- Interim Public Health Recommendations for Fully Vaccinated People
- Key Things to Know About COVID-19 Vaccines
- COVID-19 Vaccinations in the United States

Studies About SARS-CoV-2 Variants of Concern (VOC)

Studies About SARS-CoV-2 Variants of Concern

Spread, Transmissibility, and Infectivity

- Studies have shown that the B.1.617.2 SARS-CoV-2 variant is more transmissible than the early strain before major mutations (aka the "wild-type" SARS-CoV-2) in children and adults.[105-108]
  - A global analysis of the spread of SARS-CoV-2 variants found that the B.1.617.2 variant had an estimated transmissibility increase of 97%.[105]
  - [New] A study in a large healthcare setting found that from March-July 2021, the weekly percentage of infections attributed to the B.1.617.2 variant quickly increased to 95%, with infection being more common in younger people (aged 18-44 years) and among non-Hispanic Black people.[109]
- Research suggests that certain mutations present in VOCs are linked with increased transmissibility and infectivity.[110-114]
- A report of an outbreak of the B.1.617.2 variant outbreak in a gymnastics facility found that the variant had a higher secondary attack rate (spread of disease within an infected person's family or other group) compared to the other SARS-CoV-2 lineages.[115]
  - The overall attack rate was 20% in the facility and 53% in households.[115]

Current CDC Variant(s) of Concern in the US (as of 16 November 2021)[12]

Variant	WHO Label	First Detected	Other Names
B.1.617.2	Delta	India	20A/S:478K

Studies About SARS-CoV-2 Variants of Concern

Outcomes Severity for VOCs (compared to other lineages of SARS-CoV-2)

- Studies have linked B.1.617.2 variant to higher hospitalization rates than B.1.1.7 (Alpha).[116-118]
  - An examination of weekly COVID-19-related hospitalization rates among children and adolescents found that rates were 5 times higher during late June to mid-August 2021, coinciding with the predominance of the B.1.617.2 variant. Hospitalization rates were 10 times higher for unvaccinated adolescents than for vaccinated adolescents.[118]
  - [New] A study examined trends in severe outcomes before (January-June 2021) and during (July-August 2021) the B.1.617.2 variant predominance. Results showed that there were no significant increases in the proportion of people hospitalized with severe outcomes. However, younger, unvaccinated adults (aged 18-29 years) accounted for a larger proportion of those hospitalized.[119]
- A recent study in Mesa County, Colorado where the B.1.617.2 variant increased over a 3-month period to become the predominant variant in that county found that incidence, ICU admission, case fatality ratios, and breakthrough infections were significantly higher compared to other counties.[106]
- A study found that the proportion of pregnant women with COVID-19 with severe or critical illness increased as the B.1.617.2 variant become predominant.[120]
- Specific mutations that have been identified in SARS-CoV-2 variants have been associated with varying severity of COVID-19 illness.[121-123]

Studies About SARS-CoV-2 Variants of Concern

Impact of Vaccines on the Variants

- [New] Several studies have found the Pfizer-BioNTech and Moderna vaccines to be effective against infection with the B.1.617.2 variant.
  - [New] A study of a B.1.617.2 variant outbreak in a prison found the effectiveness of the Moderna vaccine to be 56.6% against infection and 84.2% against symptomatic infection.[124]
  - [New] A study of the effectiveness of the Pfizer-BioNTech vaccine against the B.1.617.2 variant among adolescents aged 12-18 years found it to be 90% effective against infection and 93% effective against symptomatic infection.[125]
  - [New] The effectiveness of the Pfizer-BioNTech vaccine against death by the B.1.617.2 variant in Scotland was 95% among persons aged 40-59 years and 87% among those aged 60 years or older. No deaths occurred among fully vaccinated persons aged 18-39 years.[126]
- Although the Pfizer-BioNTech and Moderna vaccines continue to be effective, studies indicate that their effectiveness reduced as the B.1.617.2 variant became more predominant.[127,128]
  - Studies have found that the B.1.617.2 variant exhibits some resistance to vaccine-elicited antibodies.[129-131, 132][New]

Studies About SARS-CoV-2 Variants of Concern

Impact of Vaccines on the Variants

- A study assessing the impact of variants (including B.1.617.2, B.1.1.7 [Alpha], B.1.351 [Beta], and P.1 [Gamma]) on antibodies elicited by vaccine mRNA-1273 (i.e., Moderna) showed that all individuals had responses to all variants on Day 43, the peak of response to the 2nd vaccine dose. Antibodies persisted 6 months after the 2nd dose (at lower levels), supporting studies on the potential need for booster vaccinations.[133]
- Interim analysis from an ongoing trial showed that administering a booster dose of the Moderna vaccine to healthy adults was linked with increased neutralizing antibodies (NAbs) against the wild-type virus and variants (B.1.617.2, B.1.351, and P.1).[134]

Studies About SARS-CoV-2 Variants of Concern

Continued Use of Established Mitigation Strategies

- Studies show it is critical to continue existing public health strategies (e.g., physical distancing, hand hygiene, mask wearing, people quarantining after exposure) to reduce the transmission of SARS-CoV-2 variants particularly among unvaccinated persons who have a higher transmission risk.[135-137]
- Recent studies on the rapid spread and infectivity of the B.1.617.2 variant highlight the importance of maintaining prevention strategies such as wearing masks indoors regardless of individuals' vaccination status.[112,138]
  - Recent studies examining mask requirements in K-12 school settings have linked requiring prevention strategies to lower COVID-19 pediatric case rates.[139,140]
  - [New] One study of breakthrough infections with the B.1.617.2 variant among vaccinated healthcare workers found these infections were driven by social gatherings and household exposures where people were largely unmasked. The rate of secondary infections was very low (0.75%) with most instances occurring when HCWs were not wearing masks (e.g., when eating).[141]

What Research is Still Needed About SARS-CoV-2 Variants of Concern? [2,13]

- How transmissible these variants of SARS-CoV-2 are for certain demographics (e.g., older adults)
- The likelihood of reinfection due to SARS-CoV-2 variants of concern
- How the infectious dose (amount of virus needed for infection) differs between variants of concern and the wild-type lineage
- How these variants of concern may affect existing therapies, such as vaccines

Key CDC Resources About SARS-CoV-2 Variants

- Variants and Genomic Surveillance for SARS-CoV-2
- What You Need to Know About Variants
- Variant Proportions (US COVID-19 Cases Caused by Variants)
- Understanding Variants
- Delta Variant: What We Know About the Science

Studies About the Effects of Ventilation on SARS-CoV-2

REALM PROJECT

OCLC

INSTITUTE of Museum and Library SERVICES

BATTELLE

Studies About the Effects of Ventilation on SARS-CoV-2

General Findings

- Excess CO_2 concentration has been shown to trend with relative risk of infection, but some researchers have warned against using CO_2 as a proxy for infection risk.[142-147] There are relatively inexpensive indoor air quality monitoring systems that can be used to monitor CO_2 levels in different rooms of a building.[148]
  - Monitors and smoke visualization can also be used to visualize places where stale air may accumulate (e.g., around privacy screens or large items).[149]
- Theoretically, many factors influence whether ventilation is successful in the elimination or decrease of SARS-CoV-2 particles in the air, including activities occurring in the space, occupancy rates, viral load, and various ventilation parameters.[150-152]
- Air purification or ventilation alone is not enough to decrease virus particles to below guideline levels, but ventilation, purification, and implementation of other mitigation measures (mask wearing, occupancy restrictions, surface cleaning) can reduce risk of infection drastically.[153-155]

Studies About the Effects of Ventilation on SARS-CoV-2

General Findings (Cont.)

- Researchers have proposed developing a ventilation strategy based on a high-rise building's occupancy. Adjusting air change rates as occupancy increases or decreases may help with energy efficiency and reduce electricity costs.[156]
- A study found that ventilation changes were effective at reducing mean transmission risk in classrooms by 25%, while increasing social distancing from 1.5 to 3 meters decreased transmission risk by 65%.[157]
- Researchers created an app to determine exposure times and occupancy levels based on ventilation, room specifications, and other parameters.[158]
- Modeling research has shown that the probability of infection may be influenced more by how close a person is to someone carrying SARS-CoV-2 than by the amount of fresh air in a space.[159-161]
- One study looked at impacts of various mitigation measures on long-range and short-range transmission risk. Increasing ventilation resulted in a 17-fold decrease in risk at long range, but only a 6-fold decrease in risk at close range. Additionally, the benefit of maintaining a 2m or 1m distance was dependent on air turbulence and ventilation rate in the space.[162]
- Researchers in Slovenia conducted a 125-day study of indoor air quality in kindergarten classrooms. They emphasized the need for clear, standard procedures regarding ventilation and the need to educate staff on the importance of ventilation for improving indoor air quality and mitigating virus transmission.[163]

Studies About the Effects of Ventilation on SARS-CoV-2

General Findings (Cont.)

- A study about the effects of placing dividers between patrons in public spaces (e.g., restaurants) showed limited impact on controlling airborne transmission and that dividers may cause aerosols to gather. However, the researchers still recommended use of dividers to block direct contact and spread of large droplets between patrons. The researchers also recommended that transmission risk could be reduced by cleaning the spaces created by dividers and leaving them empty (at least 6 minutes) between patrons, as well as using other tactics like increases in air change rates, social distancing, and shortening usages of the spaces.[164]
  - [New] Another group of researchers studying dividers' impact on infection risk found that a partition can effectively block expiratory particles at breathing height (in the context of diners seated at tables). However, this partition can also trap infectious particles if not enough time is allowed between diners. The researchers noted that it takes 11 minutes for the expiratory CO_2 trapped by the divider to decay to the background concentration.[165]
  - In a classroom study looking at aerosol dispersion from one source, three-sided clear dividers placed around desks resulted in reduced aerosol concentrations at monitors placed on desks. The authors noted that if desks are placed 1.5 meters or less apart, dividers may help to reduce exposure and risk of infection.[166,167]
  - [New] In another classroom study, researchers found that the amount of suspended droplets decreases as ventilation velocity increases. Generally, seats in the classroom with partitions were exposed to fewer suspended droplets than seats in the classroom without partitions.[167]
  - Another study found that a barrier height of at least 60 cm above a desk surface is needed to prevent virus transmission in spaces that are well-ventilated.[168]

Studies About the Effects of Ventilation on SARS-CoV-2

General Findings (Cont.)

- A dedicated outdoor air system (DOAS) is used in many health care settings to provide high rates of ventilation. This unit pumps 100% outdoor air into a space and is used in conjunction with an air-handling unit to heat and cool the air. DOAS are generally placed on rooftops, but new versions of the technology are smaller and more affordable.[169]

Studies About the Effects of Ventilation on SARS-CoV-2

Air Purification

- Various studies have found that air purifiers are effective in decreasing the concentrations of aerosols in a space and that purifiers are most effective if placed close to the emitter.[170-174]
- The most effective air purifiers to use against SARS-CoV-2 are those that use HEPA filters, ionizers, or ultraviolet germicidal irradiation (UVGI).[175]
- CO_2 monitors can be used to gauge the degree of ventilation in a space.[142-146] However, since air purifiers are intended to filter the air of pathogens and CO_2 monitors do not measure the presence of pathogens, the effect of air purifiers on pathogens (e.g., SARS-CoV-2) will not be captured by CO_2 monitors.
- Researchers designed and tested a low-cost air purification device using a box fan, MERV-13 filter, and a cardboard support.[176]
  - Researchers tested this purification device at approximately two air changes per hour, which is typical of a classroom built before 1989. The device reduced the risk of airborne transmission in a classroom setting, lowering the percentage of suspended aerosols in the room to as low as 1% when placed next to the ventilation source.[176]

Studies About the Effects of Ventilation on SARS-CoV-2

Air Purification (Cont.)

- Filters should fit snugly in their housings to mitigate filter bypass and should be replaced according to the instructions on the filter.[177]
- PPE should be worn when replacing air filters to reduce exposure to viral particles.[177]
- There is some evidence that the noise from mobile air purifiers (MAP) may lead to louder speech, which could result in the release of more virus particles. Researchers found that a MAP only successfully removed viral particles in a classroom under very specific circumstances (MAP close to emitter, high volume flow).[178,179]
- Air purifiers have emerged that use a process called photocatalysis. These purifiers do not use filters, but instead use UV light and a semiconductor to destroy viral particles. Research on this type of purifier is still emerging, but the advantage of purifiers that use photocatalysis is that they destroy viral particles rather than just trapping them.[180]

Studies About the Effects of Ventilation on SARS-CoV-2

HVAC Systems

- There is a risk that HVAC systems could worsen spread of COVID-19 if not designed or modified to maximize circulation of virus-free air into a space.[172,181]
- Displacement ventilation systems, or those "designed to vertically stratify indoor air by temperature (warm air at the top of the room, colder air at the bottom) and remove warmer air" were found most likely to reduce risk of SARS-CoV-2 transmission via HVAC.[164,182,183]
- Conversely, other studies found that unstable or neutrally stratified air (warm air at the bottom of the room, or no discriminate layers of warm or cold air) reduced the risk of infectious aerosols remaining at one height in the breathing environment.[145]
  - Researchers found that thermally stratified rooms (i.e., separation of warm air toward the top of a room and cooler air toward the bottom) showed higher infection risk than well-mixed rooms where social distancing of greater than 2 meters had taken place. The authors noted that the "infection risk show[ed] multiple peaks" in rooms thermally stratified using displacement ventilation, under-floor air distribution, and displacement nature ventilation (p. 7).[184]
  - [New] Additionally, researchers have found that for rooms that have floor-level heating and ceiling-level cooling, displacement or mixed ventilation systems may be best suited for reducing SARS-CoV-2-laden aerosols. In rooms with ceiling-level heating and floor-level cooling, localized ventilation systems are recommended (e.g., personalized ventilation or push-and-pull ventilation).[145]

Studies About the Effects of Ventilation on SARS-CoV-2

HVAC Systems (Cont.)

- Ventilation at only one point in a room (e.g., portable AC unit, both inlet and outlet in the ceiling) is unlikely to efficiently remove virus particles in the absence of other precautions (e.g., masks, social distancing, etc.).[149,185,186]
- Inadequate or inappropriately positioned ventilation may lead to virus hotspots or increased surface deposition.[182,185]
- Incorporation of UV-C light into duct systems was shown to inactivate 99.98% of virus in the air that passed through the duct. In-duct UV-C can also be combined with HEPA filtration.[182,187]
  - Upper room ultraviolet germicidal irradiation (UVGI) can also be used to disinfect warm air as it rises toward the ceiling. UVGI can be used with displacement ventilation or ceiling fans to continually mix and disinfect the air in the room.[181,182]

Studies About the Effects of Ventilation on SARS-CoV-2

HVAC Systems (Cont.)

- Increasing air change rates can lead to higher energy costs. These costs can be offset by 'smart' systems, which only ventilate rooms when they are occupied, and also by natural ventilation.[186,168-190]
  - While many researchers have recommended increasing air change rates to mitigate spread of COVID-19, some researchers caution that an increase in air change rate may lead to more rapid spread of infectious particles to connecting rooms or may less effectively remove particles in certain situations.[186,187]
- Air diffusers and return vents located in such a way that circulated air is contained in one physical space (also called localized flow regimes) may mitigate the spread of contaminated air.[182]
- Outdoor air dampers can be opened beyond the minimum settings to reduce indoor air recirculation (weather and temperature permitting).[177]
- It may be beneficial to run HVAC at maximum outdoor airflow for a period of time (e.g., 2 hours) before a space is occupied.[177]

Studies About the Effects of Ventilation on SARS-CoV-2

HVAC Systems (Cont.)

- Increasing the fraction of outdoor air and using a MERV-13 filter (rather than a MERV-8 filter) were found to be more likely to reduce spread of SARS-CoV-2 between adjoining rooms.[187]
- Experts recommended that exhaust fans in restrooms should operate at all times. They also noted that windows in restrooms with exhaust fans should not be opened, as exhausted air may reenter.[191]
- HVAC systems tend not to be built for airborne infection control and may only operate at a small fraction of the room air change rate needed to stop virus spread.[160]
  - Air may need to be circulated more frequently in high traffic areas (e.g., communal space and bathrooms).[161]

Studies About the Effects of Ventilation on SARS-CoV-2

Historic Buildings & Natural Ventilation

- There is divergent evidence regarding whether natural ventilation alone can decrease CO_2 amounts to below air quality recommendations.[143,146,192]
- In a study of New York City school buildings, transmission was found to be lower in older buildings compared to newer buildings, likely due to “greater outdoor airflow” (i.e., drafts). Transmission rate was also found to be lower in schools with mechanical ventilation (when compared to natural ventilation).[193]
- Findings on the impact of wind speed and direction on ventilation rates and transmission are contradictory.[142,192]
- Research remains inconclusive on whether cross-ventilation or adjacent window ventilation results in better airflow.[152,194]
- Fans can be placed in open windows to increase the effectiveness of natural ventilation. Air should exhaust to the outdoors.[158]

Studies About the Effects of Ventilation on SARS-CoV-2

Effects of Temperature & Humidity

- Because ventilation with outdoor air is more difficult in colder months, researchers have estimated that airborne infection risk is double that of summer months.[144,175,181]
  - Windows need to be opened less in winter to achieve the same ventilation rates as open windows in summer due to temperature differences between outdoor and indoor air and wind speed.[149]
  - During these months, monitoring indoor carbon dioxide as a proxy for ventilation is recommended and should not exceed 1000 ppm.[195]
  - In the absence of carbon dioxide monitoring, attention should be paid to areas with stagnant air.[195]
- Researchers recommended further studies on humidification of air, which could increase the speed at which SARS-CoV-2 particles drop to the ground or surfaces.[196]
- The taller a building is, the more prone it is to stack effect, especially in colder climates. Stack effect occurs when pressure differences between floors cause air to stagnate on upper floors. This effect may also cause a reversal of airflow and contaminants may spread to other areas of the building.[197]
- A study analyzing the effects of ventilation rate and relative humidity on airborne levels of SARS-CoV-2 found that increasing the air change rate decreased infection risk more than increasing the humidity in a space.[198]
  - [New] Further, a study analyzing the impact of humidification on SARS-CoV-2 transmission risk found that humidifying a space to 40-60% relative humidity is unlikely to significantly reduce transmission risk.[198]

What Research is Still Needed About the Impact of Ventilation on SARS-CoV-2?

- Consensus on how best to configure, upgrade, or design ventilation systems to mitigate the spread of SARS-CoV-2
  - What role thermal stratification plays in infection risk
- Whether variants that are more transmissible can be mitigated using the same ventilation methods that are effective for other strains.
- How results may differ if ventilation-related studies used SARS-CoV-2 instead of surrogate substances (e.g., carbon dioxide).
- How to best to utilize UVGI (upper room and/or in-duct) to reduce virus particles in a space.
- What impact plexiglass barriers and other dividers have on rates of spread and mitigation of SARS-CoV-2.[199]
- Regarding natural ventilation, understanding whether opening adjacent windows or windows across from each other is more effective at ventilating a space.
- The effect of wind speed and direction on natural ventilation and, consequently, transmission risk.
- Best practices for balancing energy efficiency with increased ventilation rates (and increased energy use) to mitigate transmission risk.
- The costs and benefits of all ventilation methods that could be used to reduce infection risk.[200]

Key CDC Resources About Ventilation to Mitigate SARS-CoV-2

- Ventilation in Buildings
- COVID-19 Resources for Workplaces & Businesses
- Improving Ventilation in Your Home
- Ventilation and Coronavirus (COVID-19) (Environmental Protection Agency resource)

HOW THIS BRIEFING WAS CREATED (METHODOLOGY)

How This Briefing Was Created

- In January 2021, REALM stakeholders developed Phase 3 research questions. An additional question related to ventilation was added in May 2021. In October 2021, the variants section was refocused on current variants of concern in the US.
- Battelle developed search strings that included variations of the term “SARS-CoV-2” and novel terms for vaccine and variants using Boolean operators. The Boolean operator “AND” was used to separate SARS-CoV-2 and research question terms, while different variations of the virus name and keywords related to the research question were grouped by category using parentheses and the Boolean operator “OR” (e.g., ["SARS-CoV-2" OR "2019-nCoV" OR "COVID-19"] AND [vaccine OR variant]). Search strings are included in the appendix.
- Battelle developed research question keywords using ad hoc test searches and comparison against known relevant articles. Databases were selected (Scopus, SciTech, Web of Science, and MEDLINE) to provide comprehensive search capacity and inclusion of smaller databases.
- The initial search string included a time criterion to capture articles published in January 2021 and after. Subsequent searches were executed on weekly durations. Note: when the ventilation research question was added in May 2021, articles were searched from 01 January 2021 forward to cover the same time period as the other research questions.

How This Briefing Was Created (cont.)

- Battelle staff reviewed the titles and abstracts of search results to select those most relevant to the research questions for additional examination.
- The DHS Master Question List for COVID-19 and CDC Morbidity and Mortality Weekly Reports (MMWR) were reviewed to verify the completeness of the search results (i.e., to double-check that relevant articles were not missed by the search strings).
- Battelle staff analyzed the relevant articles to identify key subtopics and prioritize high-value articles. Summaries of the articles, organized by subtopic, were presented to OCLC, IMLS, and REALM working groups for feedback.
- Battelle summarized the results for this briefing, which is a cumulative report that builds on prior briefings by adding new relevant research findings published 07 September to 01 November 2021. Additional information was also added from the CDC to provide context on the key topics, and sections have been updated over time to remove information that is no longer timely.
- Battelle will continue to review articles gathered by the search on a regular basis, and this briefing will continue to be updated iteratively with new information.

REFERENCES CITED IN THIS BRIEFING

References

1. Centers for Disease Control and Prevention (CDC). COVID data tracker [Internet]. U.S.: CDC; 2021Apr13 [2021Nov15]. Available from: https://covid.cdc.gov/covid-data-tracker/#datatracker-home
2. Department of Homeland Security (DHS) Science and Technology Directorate. Master question list for COVID-19 (caused by SARS-CoV-2). U.S.: DHS; 2021Oct6 [cited 2021Oct21]. Available from: https://www.dhs.gov/sites/default/files/publications/21_1005_st_mql_sars2_cov-2.pdf
3. U.S. Food and Drug Administration (FDA). FDA approves first COVID-19 vaccine; 2021Aug23 [cited 2021Aug 25]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine
4. Centers for Disease Control and Prevention (CDC). Pfizer-BioNTech COVID-19 Vaccine Overview and Safety (also known as COMIRNATY) [Internet]. U.S.: CDC; 2021Oct28 [cited 2021Nov16]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html
5. Centers for Disease Control and Prevention (CDC). Moderna COVID-19 vaccine overview & safety [Internet]. U.S.: CDC; 2021Oct28 [cited 2021Nov16]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html
6. Centers for Disease Control and Prevention (CDC). Johnson & Johnson's Janssen COVID-19 vaccine overview & safety [Internet]. U.S.: CDC; 2021Oct29 [cited 2021Nov16]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html
7. Centers for Disease Control and Prevention (CDC). Key things to know about COVID-19 vaccines [Internet]. U.S.: CDC;2021Nov12 [cited 2021Nov16]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/keythingstoknow.html
8. Centers for Disease Control and Prevention (CDC). COVID-19 vaccine booster shots Internet]. U.S.: CDC;2021Nov9 [cited 2021Nov16]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html
9. Centers for Disease Control and Prevention (CDC). COVID-19 vaccines for moderately to severely immunocompromised people 2021 [Internet]. U.S.: CDC; 2021Oct18 [cited 2021Oct21] Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html.

References (cont.)

10. U.S. Food and Drug Administration (FDA). Coronavirus (COVID-19) update: [Internet. U.S.: FDA; 2021Jul13 [cited 2021Jul14]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-july-13-2021
11. Centers for Disease Control and Prevention (CDC). When you've been fully vaccinated[Internet]. U.S.: CDC; 2021Oct15 [cited 2021Nov16]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html
12. Centers for Disease Control and Prevention (CDC). What you need to know about variants[Internet]. U.S.: CDC; 2021Nov1 [cited 2021Nov16]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html
13. Centers for Disease Control and Prevention (CDC). SARS-CoV-2 variant classifications and definitions [Internet]. U.S.: CDC; 2021Oct4 [cited 2021Nov16]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html
14. Centers for Disease Control and Prevention (CDC). SARS-CoV-2 Variant Classifications and Definitions. [Internet]. U.S.: CDC; 2021Oct 4. [cited 2021Oct12]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html
15. Payne S. Viruses: from understanding to investigation. [book on the internet]. Academic Press; 2017. Chapter 6: Immunity and resistance to viruses [cited 2021Jun7]; p. 61-71. Available from: https://www.sciencedirect.com/science/article/pii/B9780128031094000064
16. Hamel L, Lopes L, Sparks G, Kirzinger A, Kearney A, Stokes M, et al. KFF COVID-19 Vaccine Monitor: October 2021. 2021Oct28 [cited 2021Nov16]. Available from: https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-october-2021/
17. Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nature Medicine. 2021.
18. Jones NK, Rivett L, Seaman S, Samworth RJ, Warne B, Workman C, et al. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. eLife. 2021;10.

References (cont.)

19. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K-D, et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nature medicine. 2021.
20. Milman O, Yelin I, Aharony N, Katz R, Herzel E, Ben-Tov A, et al. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. Nature medicine. 2021.Shapiro J, Dean NE, Madewell ZJ, Yang Y, Halloran ME, Longini IM. Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and Reports. medRxiv. 2021.
21. Shapiro J, Dean NE, Madewell ZJ, Yang Y, Halloran ME, Longini IM. Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and Reports. medRxiv. 2021.
22. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers - Eight U.S. locations, December 2020-March 2021. MMWR. 2021;70(13):495-500.
23. Butchering RK, Viboud C, Howerton E, Smith CP, Truelove S, Runge MC, et al. Modeling of future COVID-19 cases, hospitalizations, and deaths, by vaccination rates and nonpharmaceutical intervention scenarios - United States, April-September 2021. MMWR;70(19):719-24.
24. Keehner J, Horton LE, Pfeffer MA, Longhurst CA, Schooley RT, Currier JS, et al. SARS-CoV-2 Infection after Vaccination in Health Care Workers in California. NEJM. 2021.
25. Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. NEJM. 2020;384(1):80-2.
26. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-29.

References (cont.)

27. Harder T, Koch J, Vygen-Bonnet S, Külper-Schiek W, Pilic A, Reda S, et al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2021;26(28).
28. Rubin D, Eisen M, Collins S, Pennington JW, Wang X, Coffin S. SARS-CoV-2 Infection in Public School District Employees Following a District-Wide Vaccination Program - Philadelphia County, Pennsylvania, March 21-April 23, 2021. MMWR Morbidity and mortality weekly report. 2021;70(30):1040-3.
29. Moline HL, Whitaker M, Deng L, Rhodes JC, Milucky J, Pham H, et al. Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years - COVID-NET, 13 States, February-April 2021. MMWR Morbidity and mortality weekly report. 2021;70(32):1088-93.
30. Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination - Kentucky, May-June 2021. MMWR Morbidity and mortality weekly report. 2021;70(32):1081-3.
31. Thomas SJ, Moreira ED, Jr., Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. The New England journal of medicine. 2021.
32. Bajema KL, Dahl RM, Prill MM, Meites E, Rodriguez-Barradas MC, Marconi VC, et al. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalization - Five Veterans Affairs Medical Centers, United States, February 1-August 6, 2021. MMWR Morbidity and mortality weekly report. 2021;70(37):1294-9.
33. Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. The New England journal of medicine. 2021;385(15):1355-71.
34. Xu S, Huang R, Sy LS, Glenn SC, Ryan DS, Morrissette K, et al. COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021. MMWR Morbidity and mortality weekly report. 2021;70(43):1520-4.

References (cont.)

35. Olson SM, Newhams MM, Halasa NB, Price AM, Boom JA, Sahni LC, et al. Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12-18 Years - United States, June-September 2021. MMWR Morbidity and mortality weekly report. 2021;70(42):1483-8.
36. U.S. Food and Drug Administration.. Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals; 2021Aug12 [cited 2021Aug 25]. Available from https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised
37. Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. The New England journal of medicine. 2021.
38. Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet (London, England). 2021;398(10309):1407-16.
39. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. The New England journal of medicine. 2021.
40. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning Immunity after the BNT162b2 Vaccine in Israel. The New England journal of medicine. 2021.
41. Gupta S, Cantor J, Simon KI, Bento AI, Wing C, Whaley CM. Vaccinations against COVID-19 may have averted up to 140,000 deaths in the United States. Health Affairs. 2021;40(9):1465-72.
42. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. NEJM. 2020;384(5):403-16.

References (cont.)

43. Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T, et al. First month of COVID-19 vaccine safety monitoring - United States, December 14, 2020-January 13, 2021. MMWR. 2021;70(8):283-8.
44. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. NEJM. 2021.
45. Sadoff J, Davis K, Douoguih M. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination - response from the manufacturer. NEJM. 2021.
46. Nguyen KH, Srivastav A, Razzaghi H, Williams W, Lindley MC, Jorgensen C, et al. COVID-19 vaccination intent, perceptions, an42d reasons for not vaccinating among groups prioritized for early vaccination - United States, September and December 2020. MMWR. 2021;70(6):217-22.
47. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. The New England journal of medicine. 2021;385(12):1078-90.
48. Tenforde MW, Self WH, Naioti EA, Ginde AA, Douin DJ, Olson SM, et al. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morbidity and mortality weekly report. 2021;70(34):1156-62.
49. Cai C, Peng Y, Shen E, Huang Q, Chen Y, Liu P, et al. A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. Molecular therapy. 2021;29(9):2794-805.
50. Fan YJ, Chan KH, Hung IF. Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3. Vaccines. 2021;9(9).

References (cont.)

51. Nguyen KH, Srivastav A,RazzaghiH, Williams W, Lindley MC, Jorgensen C, et al. COVID-19 vaccination intent, perceptions, an42d reasons for not vaccinating among groups prioritized for early vaccination -United States, September and December 2020. MMWR. 2021;70(6):217-22.
52. Webb Hooper M, Nápoles AM, Pérez-Stable EJ. No populations left behind: vaccine hesitancy and equitable diffusion of effective COVID-19 vaccines. Journal of general internal medicine. 2021:1-4.
53. Rosenblum HG, Hadler SC, Moulia D, Shimabukuro TT, Su JR, Tepper NK, et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. MMWR Morbidity and mortality weekly report. 2021;70(32):1094-9.
54. Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. The New England journal of medicine. 2021.
55. Hendren NS, Carter S, Grodin JL. Severe COVID-19 vaccine associated myocarditis: Zebra or unicorn? International journal of cardiology. 2021;343:197-8.
56. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. The New England journal of medicine. 2021.
57. Guidry JPD, Laestadius LI, Vraga EK, Miller CA, Perrin PB, Burton CW, et al. Willingness to get the COVID-19 vaccine with and without emergency use authorization. American journal of infection control. 2021;49(2):137-42.
58. Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb FJ. COVID-19 vaccination hesitancy in the united states: A rapid national assessment. Journal of community health. 2021:1-8.

References (cont.)

59. Ruiz JB, Bell RA. Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey. Vaccine. 2021;39(7):1080-6.
60. Lin C, Tu P, Beitsch LM. Confidence and receptivity for COVID-19 vaccines: A rapid systematic review. Vaccines. 2020;9(1).
61. Dodd RH, Pickles K, Nickel B, Cvejic E, Ayre J, Batcup C, et al. Concerns and motivations about COVID-19 vaccination. The Lancet Infectious diseases. 2021;21(2):161-3.
62. Momplaisir F, Haynes N, Nkwihoreze H, Nelson M, Werner RM, Jemmott J. Understanding drivers of COVID-19 vaccine hesitancy among Blacks. Clinical Infectious Diseases. 2021.
63. Paul E, Steptoe A, Fancourt D. Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. The Lancet regional health Europe. 2021;1:100012.
64. Savoia E, Piltch-Loeb R, Goldberg B, Miller-Idriss C, Hughes B, Montrond A, et al. Predictors of COVID-19 Vaccine Hesitancy: Socio-Demographics, Co-Morbidity, and Past Experience of Racial Discrimination. Vaccines. 2021;9(7).
65. Falsey AR, Frenck RW, Jr., Walsh EE, Kitchin N, Absalon J, Gurtman A, et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. The New England journal of medicine. 2021.
66. Embi PJ, Levy ME, Naleway AL, Patel P, Gaglani M, Natarajan K, et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morbidity and mortality weekly report. 2021;70(44):1553-9.
67. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. The New England journal of medicine. 2021;385(15):1393-400.
68. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet (London, England). 2021.

References (cont.)

69. Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet (London, England). 2021;398(10308):1377-80.
70. Bahl A, Johnson S, Maine G, Garcia MH, Nimmagadda S, Qu L, et al. Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study. Lancet Regional Health Americas. 2021:100065.
71. Abbasi J. COVID-19 mRNA Vaccines Blunt Breakthrough Infection Severity. Jama. 2021;326(6):473.
72. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. The New England journal of medicine. 2021.
73. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. The Lancet Infectious diseases. 2021.
74. Keehner J, Horton LE, Binkin NJ, Laurent LC, Pride D, Longhurst CA, et al. Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce. The New England journal of medicine. 2021.
75. Christie A, Henley SJ, Mattocks L, Fernando R, Lansky A, Ahmad FB, et al. Decreases in COVID-19 cases, emergency department visits, hospital admissions, and deaths among older adults following the introduction of COVID-19 vaccine - United States, September 6, 2020-May 1, 2021. MMWR. 2021;70(23):858-64.
76. Tenforde MW, Olson SM, Self WH, Talbot HK, Lindsell CJ, Steingrub JS, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines Against COVID-19 among hospitalized adults aged ≥65 Years - United States, January-March 2021. MMWR. 2021;70(18):674-9.
77. Müller L, Andrée M, Moskorz W, Drexler I, Walotka L, Grothmann R, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clinical infectious. 2021.

References (cont.)

78. Shanes ED, Otero S, Mithal LB, Mupanomunda CA, Miller ES, Goldstein JA. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination in pregnancy: Measures of immunity and placental histopathology. Obstetrics and gynecology. 2021.
79. Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. NEJM. 2021.
80. Blakeway H, Prasad S, Kalafat E, Heath PT, Ladhani SN, Le Doare K, et al. COVID-19 Vaccination During Pregnancy: Coverage and Safety. Am J Obstet Gynecol. 2021.
81. Dagan N, Barda N, Biron-Shental T, Makov-Assif M, Key C, Kohane IS, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nature medicine. 2021.
82. Murthy BP, Sterrett N, Weller D, Zell E, Reynolds L, Toblin RL, et al. Disparities in COVID-19 vaccination coverage between urban and rural counties - United States, December 14, 2020-April 10, 2021. MMWR. 2021;70(20):759-64.
83. Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the bnt162b2 covid-19 vaccine in adolescents. NEJM. 2021.
84. Wallace M, Woodworth KR, Gargano JW, Scobie HM, Blain AE, Moulia D, et al. The Advisory Committee on Immunization Practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years - United States, May 2021. MMWR Morbidity and mortality weekly report. 2021;70(20):749-52.
85. Hause AM, Gee J, Baggs J, Abara WE, Marquez P, Thompson D, et al. COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021. MMWR Morbidity and mortality weekly report. 2021;70(31):1053-8.
86. Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. The New England journal of medicine. 2021.

References (cont.)

87. Gorga SM, Brandt EJ, Rosenberg J, Waselewski ME, Amaro X, Chang T. Youth Perceptions of Vaccination for COVID-19 in the United States. JAMA Health Forum. 2021;2(8):e212103-e.
88. Yan Z, Yang M, Lai CL. COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations. Vaccines. 2021;9(10).
89. Lin C, Tu P, Beitsch LM. Confidence and receptivity for COVID-19 vaccines: A rapid systematic review. Vaccines. 2020;9(1).
90. Rzymski P, Borkowski L, Drąg M, Flisiak R, Jemielity J, Krajewski J, et al. The strategies to support the COVID-19 vaccination with evidence-based communication and tackling misinformation. Vaccines. 2021;9(2).
91. Loomba S, de Figueiredo A, Piatek SJ, de Graaf K, Larson HJ. Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. Nature Human Behaviour. 2021.
92. Marco-Franco JE, Pita-Barros P, Vivas-Orts D, González-de-Julián S, Vivas-Consuelo D. COVID-19, fake news, and vaccines: Should regulation be implemented? International journal of environmental research and public health. 2021;18(2):744.
93. Benham JL, Lang R, Kovacs Burns K, MacKean G, Léveillé T, McCormack B, et al. Attitudes, current behaviours and barriers to public health measures that reduce COVID-19 transmission: A qualitative study to inform public health messaging. PloS one. 2021;16(2):e0246941-e.
94. The National Academies of Sciences, Engineering, and Medicine. To increase confidence in COVID-19 vaccines, decision-makers need to showcase public support, leverage endorsements, focus on hesitant individuals, and engage communities. U.S.: The National Academies of Sciences, Engineering, and Medicine 2021Feb3 [cited 2021May12]. Available from: https://www.nationalacademies.org/news/2021/02/to-increase-confidence-in-covid-19-vaccines-decision-makers-need-to-showcase-public-support-leverage-endorsements-focus-on-hesitant-individuals-and-engage-communities

References (cont.)

95. Balasuriya L, Santilli A, Morone J, Ainooson J, Roy B, Njoku A, et al. COVID-19 Vaccine Acceptance and Access Among Black and Latinx Communities. JAMA network open. 2021;4(10):e2128575.
96. Pingali C, Meghani M, Razzaghi H, Lamias MJ, Weintraub E, Kenigsberg TA, et al. COVID-19 Vaccination Coverage Among Insured Persons Aged ≥16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morbidity and mortality weekly report. 2021;70(28):985-90.
97. Kirksey L, Milam AJ, Curry CW, Sorour AA. Vaccine hesitance and vaccine access in minority communities. Cleveland Clinic journal of medicine. 2021.
98. Laurencin CT. Addressing justified vaccine hesitancy in the Black community. Journal of racial and ethnic health disparities. 2021:1-4.
99. Reverby SM. Racism, disease, and vaccine refusal: People of color are dying for access to COVID-19 vaccines. PLoS biology. 2021;19(3):e3001167.
100. Thompson HS, Manning M, Mitchell J, Kim S, Harper FWK, Cresswell S, et al. Factors associated with racial/ethnic group-based medical mistrust and perspectives on COVID-19 vaccine trial participation and vaccine uptake in the US. JAMA network open. 2021;4(5):e2111629.
101. Hildreth JEK, Alcendor DJ. Targeting COVID-19 vaccine hesitancy in minority populations in the US: implications for herd immunity. Vaccines. 2021;9(5).
102. Barry V, Dasgupta S, Weller DL, Kriss JL, Cadwell BL, Rose C, et al. Patterns in COVID-19 Vaccination Coverage, by Social Vulnerability and Urbanicity - United States, December 14, 2020-May 1, 2021. MMWR Morbidity and mortality weekly report. 2021;70(22):818-24.

References (cont.)

103. Ryerson AB, Rice CE, Hung MC, Patel SA, Weeks JD, Kriss JL, et al. Disparities in COVID-19 Vaccination Status, Intent, and Perceived Access for Noninstitutionalized Adults, by Disability Status - National Immunization Survey Adult COVID Module, United States, May 30-June 26, 2021. MMWR Morbidity and mortality weekly report. 2021;70(39):1365-71.
104. Kwok HF. Review of Covid-19 vaccine clinical trials - A puzzle with missing pieces. International journal of biological sciences. 2021;17(6):1461-8.
105. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2021;26(24).
106. Herlihy R, Bamberg W, Burakoff A, Alden N, Severson R, Bush E, et al. Rapid Increase in Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - Mesa County, Colorado, April-June 2021. MMWR Morbidity and mortality weekly report. 2021;70(32):1084-7.
107. Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021. MMWR Morbidity and mortality weekly report. 2021;70(31):1059-62.
108. Somekh I, Stein M, Karakis I, Simões EAF, Somekh E. Characteristics of SARS-CoV-2 Infections in Israeli Children During the Circulation of Different SARS-CoV-2 Variants. JAMA network open. 2021;4(9):e2124343.
109. Malden DE, Bruxvoort KJ, Tseng HF, Ackerson B, Choi SK, Florea A, et al. Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System - California, March-July 2021. MMWR Morbidity and mortality weekly report. 2021;70(40):1415-9.
110. Hu J, Peng P, Wang K, Fang L, Luo FY, Jin AS, et al. Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. Cellular & molecular immunology. 2021;18(4):1061-3.

References (cont.)

111. Wang R, Chen J, Gao K, Hozumi Y, Yin C, Wei GW. Analysis of SARS-CoV-2 mutations in the United States suggests presence of four substrains and novel variants. Communications biology. 2021;4(1):228.

112. Zhao S, Lou J, Cao L, Zheng H, Chong MKC, Chen Z, et al. Modelling the association between COVID-19 transmissibility and D614G substitution in SARS-CoV-2 spike protein: using the surveillance data in California as an example. Theoretical biology & medical modelling. 2021;18(1):10.

113. Pereira F. SARS-CoV-2 variants combining spike mutations and the absence of ORF8 may be more transmissible and require close monitoring. Biochemical and biophysical research communications. 2021;550:8-14.

114. Ives AR, Bozzuto C. Estimating and explaining the spread of COVID-19 at the county level in the USA. Communications biology. 2021;4(1):60.

115. Dougherty K, Mannell M, Naqvi O, Matson D, Stone J. SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Outbreak Associated with a Gymnastics Facility - Oklahoma, April-May 2021. MMWR Morbidity and mortality weekly report. 2021;70(28):1004-7.

116. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet (London, England). 2021;397(10293):2461-2.

117. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. The Lancet Infectious diseases. 2021.

118. Delahoy MJ, Ujamaa D, Whitaker M, O'Halloran A, Anglin O, Burns E, et al. Hospitalizations Associated with COVID-19 Among Children and Adolescents - COVID-NET, 14 States, March 1, 2020-August 14, 2021. MMWR Morbidity and mortality weekly report. 2021;70(36):1255-60.

References (cont.)

119. Taylor CA, Patel K, Pham H, Whitaker M, Anglin O, Kambhampati AK, et al. Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance - COVID-NET, 14 States, January-August 2021. MMWR Morbidity and mortality weekly report. 2021;70(43):1513-9.
120. Adhikari EH, SoRelle JA, McIntire DD, Spong CY. Increasing severity of COVID-19 in pregnancy with Delta (B.1.617.2) variant surge. Am J Obstet Gynecol. 2021.
121. Nagy Á, Pongor S, Győrffy B. Different mutations in SARS-CoV-2 associate with severe and mild outcome. International journal of antimicrobial agents. 2021;57(2):106272.
122. Groves DC, Rowland-Jones SL, Angyal A. The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design. Biochemical and biophysical research communications. 2021;538:104-7.
123. Goyal M, De Bruyne K, van Belkum A, West B. Different SARS-CoV-2 haplotypes associate with geographic origin and case fatality rates of COVID-19 patients. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2021;90:104730.
124. Chin ET, Leidner D, Zhang Y, Long E, Prince L, Li Y, et al. Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison. The New England journal of medicine. 2021.
125. Reis BY, Barda N, Leshchinsky M, Kepten E, Hernán MA, Lipsitch M, et al. Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents. The New England journal of medicine. 2021.
126. Sheikh A, Robertson C, Taylor B. BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant. The New England journal of medicine. 2021.

References (cont.)

127. Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K. Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021. MMWR Morbidity and mortality weekly report. 2021;70(34):1167-9.
128. Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. MMWR Morbidity and mortality weekly report. 2021;70(34):1163-6.
129. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. The New England journal of medicine. 2021.
130. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet (London, England). 2021;397(10292):2331-3.
131. Tada T, Zhou H, Samanovic MI, Dcosta BM, Cornelius A, Mulligan MJ, et al. Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants. bioRxiv. 2021.
132. Arora P, Sidarovich A, Krüger N, Kempf A, Nehlmeier I, Graichen L, et al. B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. Cell reports. 2021;37(2):109825.
133. Pegu A, O'Connell S, Schmidt SD, O'Dell S, Talana CA, Lai L, et al. Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants. bioRxiv. 2021.
134. Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. Nature medicine. 2021.

References (cont.)

135. Grubaugh ND, Hodcroft EB, Fauver JR, Phelan AL, Cevik M. Public health actions to control new SARS-CoV-2 variants. Cell. 2021;184(5):1127-32.

136. Moore JP, Offit PA. SARS-CoV-2 vaccines and the growing threat of viral variants. JAMA. 2021;325(9):821-2.

137. Lam-Hine T, McCurdy SA, Santora L, Duncan L, Corbett-Detig R, Kapusinszky B, et al. Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School - Marin County, California, May-June 2021. MMWR Morbidity and mortality weekly report. 2021;70(35):1214-9.

138. Luo CH, Morris CP, Sachithanandham J, Amadi A, Gaston D, Li M, et al. Infection with the SARS-CoV-2 Delta Variant is Associated with Higher Infectious Virus Loads Compared to the Alpha Variant in both Unvaccinated and Vaccinated Individuals. medRxiv. 2021.

139. Jehn M, McCullough JM, Dale AP, Gue M, Eller B, Cullen T, et al. Association Between K-12 School Mask Policies and School-Associated COVID-19 Outbreaks - Maricopa and Pima Counties, Arizona, July-August 2021. MMWR Morbidity and mortality weekly report. 2021;70(39):1372-3.

140. Budzyn SE, Panaggio MJ, Parks SE, Papazian M, Magid J, Eng M, et al. Pediatric COVID-19 Cases in Counties With and Without School Mask Requirements - United States, July 1-September 4, 2021. MMWR Morbidity and mortality weekly report. 2021;70(39):1377-8.

141. Waldman SE, Buehring T, Escobar DJ, Gohil SK, Gonzales R, Huang SS, et al. Secondary Cases of Delta-Variant COVID-19 Among Vaccinated Healthcare Workers with Breakthrough Infections is Rare. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021.

142. Tung CW, Mak CM, Niu JL, Hung K, Wu Y, Tung N, Wong HM. Enlightenment of re-entry airflow: The path of the airflow and the airborne pollutants transmission in buildings. Building and Environment. 2021 May 15;195:107760.

References (cont.)

143. Vassella CC, Koch J, Henzi A, Jordan A, Waeber R, Iannaccone R, Charrière R. From spontaneous to strategic natural window ventilation: Improving indoor air quality in Swiss schools. International Journal of Hygiene and Environmental Health. 2021 May 1;234:113746.

144. Vouriot CV, Burridge HC, Noakes CJ, Linden PF. Seasonal variation in airborne infection risk in schools due to changes in ventilation inferred from monitored carbon dioxide. Indoor air. 2021 Mar 8.

145. Deng X, Gong G, He X, Shi X, Mo L. Control of exhaled SARS-CoV-2-laden aerosols in the interpersonal breathing microenvironment in a ventilated room with limited space air stability. Journal of Environmental Sciences. 2021 Oct 1;108:175-87

146. Di Gilio A, Palmisani J, Pulimeno M, Cerino F, Cacace M, Miani A, et al. CO(2) concentration monitoring inside educational buildings as a strategic tool to reduce the risk of Sars-CoV-2 airborne transmission. Environmental research. 2021;202:111560.

147. Stabile L, Pacitto A, Mikszewski A, Morawska L, Buonanno G. Ventilation procedures to minimize the airborne transmission of viruses in classrooms. Build Environ. 2021;202:108042.

148. Peng Z, Jimenez JL. Exhaled CO2 as a COVID-19 Infection Risk Proxy for Different Indoor Environments and Activities. Environmental Science & Technology Letters. 2021;8(5):392-7.

149. British Occupational Hygiene Society. COVID-19 and ventilation frequently asked questions .2021 [cited 2021Jul14]; Available from: https://mk0bohsx5kak7rlajjs.kinstacdn.com/app/uploads/2021/06/COVID-19-and-Ventilation-FAQs.pdf

150. Jones B, Sharpe P, Iddon C, Hathway EA, Noakes CJ, Fitzgerald S. Modelling uncertainty in the relative risk of exposure to the SARS-CoV-2 virus by airborne aerosol transmission in well mixed indoor air. Building and environment. 2021 Mar 15;191:107617.

151. Sarti D, Campanelli T, Rondina T, Gasperini B. COVID-19 in Workplaces: Secondary Transmission. Annals of work exposures and health. 2021.

References (cont.)

152. Ahmadzadeh M, Farokhi E, Shams M. Investigating the effect of air conditioning on the distribution and transmission of COVID-19 virus particles. Journal of cleaner production. 2021;316:128147.
153. Blocken B, van Druenen T, Ricci A, Kang L, van Hooff T, Qin P, Xia L, Ruiz CA, Arts JH, Diepens JF, Maas GA. Ventilation and air cleaning to limit aerosol particle concentrations in a gym during the COVID-19 pandemic. Building and Environment. 2021 Apr 15;193:107659.
154. D'Orazio M, Bernardini G, Quagliarini E. A probabilistic model to evaluate the effectiveness of main solutions to COVID-19 spreading in university buildings according to proximity and time-based consolidated criteria.
155. Kennedy, M.; Lee, S. J.; Epstein, M., Modeling aerosol transmission of SARS-CoV-2 in multi-room facility. Journal of Loss Prevention in the Process Industries 2020, 104336.
156. Sha H, Zhang X, Qi D. Optimal control of high-rise building mechanical ventilation system for achieving low risk of COVID-19 transmission and ventilative cooling. Sustainable cities and society. 2021;74:103256.
157. Zafarnejad R, Griffin PM. Assessing school-based policy actions for COVID-19: An agent-based analysis of incremental infection risk. Computers in biology and medicine. 2021;134:104518.
158. Bazant MZ, Bush JW. Beyond six feet: A guideline to limit indoor airborne transmission of COVID-19. medRxiv. 2020 Jan 1.
159. Guo Y, Qian H, Sun Z, Cao J, Liu F, Luo X, et al. Assessing and controlling infection risk with Wells-Riley model and spatial flow impact factor (SFIF). Sustainable cities and society. 2021;67:102719.
160. Nardell EA. Air disinfection for airborne infection control with a focus on COVID-19: why germicidal UV is essential. Photochemistry and photobiology. 2021;97(3):493-7.

References (cont.)

161. Sodiq A, Khan MA, Naas M, Amhamed A. Addressing COVID-19 contagion through the HVAC systems by reviewing indoor airborne nature of infectious microbes: Will an innovative air recirculation concept provide a practical solution? Environmental research. 2021;199:111329.

162. Wagner J, Sparks TL, Miller S, Chen W, Macher JM, Waldman JM. Modeling the impacts of physical distancing and other exposure determinants on aerosol transmission. Journal of occupational and environmental hygiene. 2021:1-15.

163. Lovec V, Premrov M, Leskovar V. Practical Impact of the COVID-19 Pandemic on Indoor Air Quality and Thermal Comfort in Kindergartens. A Case Study of Slovenia. International journal of environmental research and public health. 2021;18(18).

164. Liu Z, Li R, Wu Y, Ju R, Gao N. Numerical study on the effect of diner divider on the airborne transmission of diseases in canteens. Energy and buildings. 2021;248:111171.

165. Ye J, Ai Z, Zhang C. A new possible route of airborne transmission caused by the use of a physical partition. Journal of Building Engineering. 2021;44:103420.

166. Dacunto P, Moser D, Ng A, Benson M. Classroom aerosol dispersion: desk spacing and divider impacts. International journal of environmental science and technology : IJEST. 2021:1-14.

167. Mirzaie M, Lakzian E, Khan A, Warkiani ME, Mahian O, Ahmadi G. COVID-19 spread in a classroom equipped with partition - A CFD approach. Journal of hazardous materials. 2021;420:126587.

168. Ren C, Xi C, Wang J, Feng Z, Nasiri F, Cao SJ, et al. Mitigating COVID-19 infection disease transmission in indoor environment using physical barriers. Sustainable cities and society. 2021;74:103175.

169. Turpin JR. Healthcare applications can benefit from direct outdoor air systems 2021 [updated June 28, 2021. [cited 2021Jul14] Available from: https://www.achrnews.com/articles/145113-healthcare-applications-can-benefit-from-direct-outdoor-air-systems.

References (cont.)

170. Zacharias N, Haag A, Brang-Lamprecht R, Gebel J, Essert SM, Kistemann T, Exner M, Mutters NT, Engelhart S. Air filtration as a tool for the reduction of viral aerosols. Science of The Total Environment. 2021 Jun 10;772:144956.
171. Curtius J, Granzin M, Schrod J. Testing mobile air purifiers in a school classroom: Reducing the airborne transmission risk for SARS-CoV-2. Aerosol Science and Technology. 2021 Mar 25;55(5):586-99.
172. Narayanan SR, Yang S. Airborne transmission of virus-laden aerosols inside a music classroom: Effects of portable purifiers and aerosol injection rates. Physics of Fluids. 2021 Mar 1;33(3):033307.
173. Burgmann S, Janoske U. Transmission and reduction of aerosols in classrooms using air purifier systems. Physics of Fluids. 2021 Mar 23;33(3):033321.
174. Zhai Z, Li H, Bahl R, Trace K. Application of Portable Air Purifiers for Mitigating COVID-19 in Large Public Spaces. Buildings. 2021;11(8):329.
175. Agarwal N, Meena CS, Raj BP, Saini L, Kumar A, Gopalakrishnan N, et al. Indoor air quality improvement in COVID-19 pandemic: Review. Sustainable cities and society. 2021;70:102942.
176. He R, Liu W, Elson J, Vogt R, Maranville C, Hong J. Airborne transmission of COVID-19 and mitigation using box fan air cleaners in a poorly ventilated classroom. Phys Fluids (1994). 2021;33(5):057107.
177. Afshari A, Hultmark G, Nielsen PV, Maccarini A. Ventilation system design and the coronavirus (COVID-19). Frontiers in Built Environment Front Built Environ. 2021;7(April):662489.
178. Seipp H, Steffens T. Air hygiene in classrooms under sars-cov-2 conditions–part 2: Aerosol separation and influence on thermal comfort by mobile air purifiers. Gefahrstoffe Reinhaltung der Luft. 2021:135-46.

References (cont.)

179. Steffens T, Seipp H. Air hygiene in classrooms under SARS-CoV-2 conditions-Part I: Effects of noise exposure when using mobile air purifiers (MAP). Gefahrstoffe Reinhaltung Der Luft. 2021:127-34.
180. Poormohammadi A, Bashirian S, Rahmani AR, Azarian G, Mehri F. Are photocatalytic processes effective for removal of airborne viruses from indoor air? A narrative review. Environmental science and pollution research international. 2021:1-14.
181. Yu J, Kim C, Lee YG, Bae S. Impact on airborne virus behavior by an electric heat pump (EHP) operation in a restaurant during winter season. Building and Environment. 2021;200:107951.
182. Qiao Y, Yang M, Marabella IA, McGee DAJ, Aboubakr H, Goyal S, et al. Greater than 3-log reduction in viable coronavirus aerosol concentration in ducted ultraviolet-c (UV-C) systems. Environ Sci Technol. 2021;55(7):4174-82.
183. Barbosa BPP, Brum NdCL. Ventilation mode performance against airborne respiratory infections in small office spaces: limits and rational improvements for Covid-19. Journal of the Brazilian Society of Mechanical Sciences and Engineering. 2021;43(6):1-19.
184. Liu F, Luo Z, Li Y, Zheng X, Zhang C, Qian H. Revisiting physical distancing threshold in indoor environment using infection-risk-based modeling. Environment international. 2021;153:106542.
185. Shao S, Zhou D, He R, Li J, Zou S, Mallery K, Kumar S, Yang S, Hong J. Risk assessment of airborne transmission of COVID-19 by asymptomatic individuals under different practical settings. Journal of aerosol science. 2021 Jan 1;151:105661
186. Mariam, Magar A, Joshi M, Rajagopal PS, Khan A, Rao MM, et al. CFD Simulation of the Airborne Transmission of COVID-19 Vectors Emitted during Respiratory Mechanisms: Revisiting the Concept of Safe Distance. ACS omega. 2021;6(26):16876-89.
187. Pease LF, Wang N, Salsbury TI, Underhill RM, Flaherty JE, Vlachokostas A, Kulkarni G, James DP. Investigation of potential aerosol transmission and infectivity of SARS-CoV-2 through central ventilation systems. Building and Environment. 2021 197: 107633.
188. Allen JG, Ibrahim AM. Indoor Air Changes and Potential Implications for SARS-CoV-2 Transmission. Jama. 2021;325(20):2112-3.

References (cont.)

189. Wang J, Huang J, Feng Z, Cao SJ, Haghighat F. Occupant-density-detection based energy efficient ventilation system: Prevention of infection transmission. Energy and buildings. 2021;240:110883.

190. Schibuola L, Tambani C. Performance comparison of heat recovery systems to reduce viral contagion in indoor environments. Applied Thermal Engineering. 2021;190:116843.

191. Kurabuchi T, Yanagi U, Ogata M, Otsuka M, Kagi N, Yamamoto Y, et al. Operation of air-conditioning and sanitary equipment for SARS-CoV-2 infectious disease control. Japan Architectural Review. 2021.

192. Alaidroos, A., Almaimani, A., Baik, A., Al-Amodi, M.,Rahaman, K.R., 2021. Are historical buildings more adaptive to minimize the risks of airborne transmission of viruses and public health? A study of the Hazzazi House in Jeddah (Saudi Arabia). International Journal of Environmental Research and Public Health, 18(7), p.3601.

193. Pavilonis B, Ierardi AM, Levine L, Mirer F, Kelvin EA. Estimating aerosol transmission risk of SARS-CoV-2 in New York City public schools during reopening. Environmental Research. 2021 Apr 1;195:110805.

194. Abbas GM, Dino IG. The impact of natural ventilation on airborne biocontaminants: a study on COVID-19 dispersion in an open office. Engineering, Construction and Architectural Management. 2021.

195. Burridge HC, Bhagat RK, Stettler ME, Kumar P, De Mel I, Demis P, Hart A, Johnson-Llambias Y, King MF, Klymenko O, McMillan A. The ventilation of buildings and other mitigating measures for COVID-19: a focus on wintertime. Proceedings of the Royal Society A. 2021 Mar 31;477(2247):20200855..

196. Arias FJ, De Las Heras S. The mechanical effect of moisturization on airborne COVID-19 transmission and its potential use as control technique. Environmental research. 2021 Jun 1;197:110940.

References (cont.)

197. McKeen P, Liao Z. The influence of airtightness on contaminant spread in MURBs in cold climates. Building simulation. 2021:1-16.
198. Aganovic A, Bi Y, Cao G, Drangsholt F, Kurnitski J, Wargocki P. Estimating the impact of indoor relative humidity on SARS-CoV-2 airborne transmission risk using a new modification of the Wells-Riley model. Build Environ. 2021;205:108278.
199. Addleman S, Leung V, Asadi L, Sharkawy A, McDonald J. Mitigating airborne transmission of SARS-CoV-2. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2021.
200. Berry G, Parsons A, Morgan M, Rickert J, Cho H. A review of methods to reduce the probability of the airborne spread of COVID-19 in ventilation systems and enclosed spaces. Environmental research. 2021;203:111765.

APPENDIX: SEARCH STRINGS

Database	Strategy: Vaccines and Variants of SARS-CoV-2
Scopus	((TITLE-ABS (coronavir* OR covid OR "COVID-19" OR "SARS-CoV-2" OR "2019-nCoV") AND TITLE-ABS (spread* OR transmi* OR infect* OR reinfect* OR virulence OR neutraliz* OR sever* OR evad* OR airborne OR aerosol* OR occupation* OR infectiv* OR mortality OR morbidity OR death*) AND TITLE-ABS (variant OR vaccine OR mutat* OR mutant* OR lineage OR immun* OR strain)) AND NOT TITLE-ABS (receptor OR inflamm* OR peptide* OR nanomaterial OR ace2 OR polymerase OR "IgA" OR patient* OR assay* OR ligand* OR protease OR hiv))
SciTech	(ti,ab(coronavir* OR covid OR "COVID-19" OR "SARS-CoV-2" OR "2019-nCoV") AND ti,ab(spread* OR transmi* OR infect* OR reinfect* OR virulence OR neutraliz* OR sever* OR evad* OR airborne OR aerosol* OR occupation* OR infectiv* OR mortality OR morbidity OR death*) AND ti,ab(variant OR vaccine OR mutat* OR mutant* OR lineage OR immun* OR strain)) NOT ti,ab(receptor OR inflamm* OR peptide* OR nanomaterial OR ace2 OR polymerase OR "IgA" OR patient* OR assay* OR ligand* OR protease OR hiv)
Web of Science	TS=(coronavir* OR covid OR "COVID-19" OR "SARS-CoV-2" OR "2019-nCoV") AND TS=(spread* OR transmi* OR infect* OR reinfect* OR virulence OR neutraliz* OR sever* OR evad* OR airborne OR aerosol* OR occupation* OR infectiv* OR mortality OR morbidity OR death*) AND TS=(variant OR vaccine OR mutat* OR mutant* OR lineage OR immun* OR strain) NOT TS=(receptor OR inflamm* OR peptide* OR nanomaterial OR ace2 OR polymerase OR "IgA" OR patient* OR assay* OR ligand* OR protease OR hiv)
MEDLINE	(TI (coronavir* OR covid OR "COVID-19" OR "SARS-CoV-2" OR "2019-nCoV") AND TI (spread* OR transmi* OR infect* OR reinfect* OR virulence OR neutraliz* OR sever* OR evad* OR airborne OR aerosol* OR occupation* OR infectiv* OR mortality OR morbidity OR death*) AND TI (variant OR vaccine OR mutat* OR mutant* OR lineage OR immun* OR strain) NOT TI (receptor OR inflamm* OR peptide* OR nanomaterial OR ace2 OR polymerase OR "IgA" OR patient* OR assay* OR ligand* OR protease OR hiv)) OR (AB (coronavir* OR covid OR "COVID-19" OR "SARS-CoV-2" OR "2019-nCoV") AND AB (spread* OR transmi* OR infect* OR reinfect* OR virulence OR neutraliz* OR sever* OR evad* OR airborne OR aerosol* OR occupation* OR infectiv* OR mortality OR morbidity OR death*) AND AB (variant OR vaccine OR mutat* OR mutant* OR lineage OR immun* OR strain) NOT AB (receptor OR inflamm* OR peptide* OR nanomaterial OR ace2 OR polymerase OR "IgA" OR patient* OR assay* OR ligand* OR protease OR hiv))

Database	Strategy: Effects of Ventilation on Spread of SARS-CoV-2
Scopus	(TITLE-ABS (coronavir* OR covid OR "COVID-19" OR "SARS-CoV-2" OR "2019-nCoV") AND TITLE-ABS (spread* OR transmi* OR persist* OR mitigat* OR purif* OR reduc*) AND TITLE-ABS (indoor OR office OR "climate controlled" OR ambient OR air OR airborne OR aerosol* OR hvac OR merv OR filter* OR filtrat* OR ventilat* OR hepa)) AND NOT TITLE-ABS (pollution OR particulate* OR hospital* OR nosocomial OR animal OR wastewater OR sewage OR "intensive care" OR patient OR phenotype OR clinical OR polymerase) AND (LIMIT-TO (PUBYEAR , 2021))
SciTech	(TS=(coronavir* OR covid OR "COVID-19" OR "SARS-CoV-2" OR "2019-nCoV") AND TS=(spread* OR transmi* OR persist* OR mitigat* OR purif* OR reduc*) AND TS=(indoor OR office OR "climate controlled" OR ambient OR air OR airborne OR aerosol* OR hvac OR merv OR filter* OR filtrat* OR ventilat* OR hepa)) NOT TS=(pollution OR particulate* OR hospital* OR nosocomial OR animal OR wastewater OR sewage OR "intensive care" OR patient OR phenotype OR clinical OR polymerase) AND PUB YEAR= 2021
Web of Science	(TI (coronavir* OR covid OR "COVID-19" OR "SARS-CoV-2" OR "2019-nCoV") OR AB (coronavir* OR covid OR "COVID-19" OR "SARS-CoV-2" OR "2019-nCoV")) AND (TI (spread* OR transmi* OR persist* OR mitigat* OR purif* OR reduc*) OR AB (spread* OR transmi* OR persist* OR mitigat* OR purif* OR reduc*)) AND (TI (indoor OR office OR "climate controlled" OR ambient OR air OR airborne OR aerosol* OR hvac OR merv OR filter* OR filtrat* OR ventilat* OR hepa) OR AB (indoor OR office OR "climate controlled" OR ambient OR air OR airborne OR aerosol* OR hvac OR merv OR filter* OR filtrat* OR ventilat* OR hepa)) NOT (TI (pollution OR particulate* OR hospital* OR nosocomial OR animal OR wastewater OR sewage OR "intensive care" OR patient OR phenotype OR clinical OR polymerase) OR AB (pollution OR particulate* OR hospital* OR nosocomial OR animal OR wastewater OR sewage OR "intensive care" OR patient OR phenotype OR clinical OR polymerase)) Date of Publication: 20210101-20211231
MEDLINE	(ti,ab(coronavir* OR covid OR "COVID-19" OR "SARS-CoV-2" OR "2019-nCoV") AND ti,ab(spread* OR transmi* OR persist* OR mitigat* OR purif* OR reduc*) AND ti,ab(indoor OR office OR "climate controlled" OR ambient OR air OR airborne OR aerosol* OR hvac OR merv OR filter* OR filtrat* OR ventilat* OR hepa)) NOT ti,ab(pollution OR particulate* OR hospital* OR nosocomial OR animal OR wastewater OR sewage OR "intensive care" OR patient OR phenotype OR clinical OR polymerase) Date: After January 01 2021

REALM PROJECT

REopening Archives, Libraries, and Museums

oc.lc/realm-project

#REALMproject